![Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes: Trends in Endocrinology & Metabolism Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes: Trends in Endocrinology & Metabolism](https://www.cell.com/cms/attachment/2119047448/2088486159/gr1.jpg)
Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes: Trends in Endocrinology & Metabolism
![GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes | Nature Reviews Nephrology GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes | Nature Reviews Nephrology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fnrneph.2017.123/MediaObjects/41581_2017_Article_BFnrneph2017123_Fig1_HTML.jpg)
GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes | Nature Reviews Nephrology
Mechanisms by which GLP-1 agonists may exert beneficial effects on the... | Download Scientific Diagram
![GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus | Nature Reviews Endocrinology GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus | Nature Reviews Endocrinology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fnrendo.2012.140/MediaObjects/41574_2012_Article_BFnrendo2012140_Fig1_HTML.jpg)
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus | Nature Reviews Endocrinology
Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists Specifically Optimized for Multidose Formulations | Journal of Medicinal Chemistry
![GLP-1 analog reduces major CV outcomes in patients with atherosclerotic poly-vascular disease - PACE-CME GLP-1 analog reduces major CV outcomes in patients with atherosclerotic poly-vascular disease - PACE-CME](https://pace-cme.org/2018/05/16/glp-1-analog-reduces-major-cv-outcomes-in-patients-with-atherosclerotic-poly-vascular-disease/images/GLP-1-analog-reduces-major-CV-outcomes-in-patients-with-atherosclerotic-poly-vascular-disease-2x.jpg)
GLP-1 analog reduces major CV outcomes in patients with atherosclerotic poly-vascular disease - PACE-CME
![What are the gastrointestinal adverse effects of the glucagon-like peptide 1 receptor agonists, and how should they be managed? | Illinois ADVANCE What are the gastrointestinal adverse effects of the glucagon-like peptide 1 receptor agonists, and how should they be managed? | Illinois ADVANCE](https://illinoisadvance.com/media/images/GLP-1_RA_1.31.22_2.original.png)
What are the gastrointestinal adverse effects of the glucagon-like peptide 1 receptor agonists, and how should they be managed? | Illinois ADVANCE
![Endothelial GLP-1 (Glucagon-Like Peptide-1) Receptor Mediates Cardiovascular Protection by Liraglutide In Mice With Experimental Arterial Hypertension | Arteriosclerosis, Thrombosis, and Vascular Biology Endothelial GLP-1 (Glucagon-Like Peptide-1) Receptor Mediates Cardiovascular Protection by Liraglutide In Mice With Experimental Arterial Hypertension | Arteriosclerosis, Thrombosis, and Vascular Biology](https://www.ahajournals.org/cms/asset/9321b2aa-a6c2-464f-8783-d5da1022514e/145ga1.jpg)
Endothelial GLP-1 (Glucagon-Like Peptide-1) Receptor Mediates Cardiovascular Protection by Liraglutide In Mice With Experimental Arterial Hypertension | Arteriosclerosis, Thrombosis, and Vascular Biology
![Insights into a possible role of glucagon-like peptide-1 receptor agonists in the treatment of depression | Pharmacological Reports Insights into a possible role of glucagon-like peptide-1 receptor agonists in the treatment of depression | Pharmacological Reports](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs43440-021-00274-8/MediaObjects/43440_2021_274_Figa_HTML.png)
Insights into a possible role of glucagon-like peptide-1 receptor agonists in the treatment of depression | Pharmacological Reports
![Classification of currently available glucagon-like peptide-1 receptor... | Download Scientific Diagram Classification of currently available glucagon-like peptide-1 receptor... | Download Scientific Diagram](https://www.researchgate.net/publication/301686893/figure/fig1/AS:406667536683008@1473968504066/Classification-of-currently-available-glucagon-like-peptide-1-receptor-agonists-GLP-1.png)
Classification of currently available glucagon-like peptide-1 receptor... | Download Scientific Diagram
![GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes | Circulation GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes | Circulation](https://www.ahajournals.org/cms/asset/96c991b5-3fb8-4715-93b4-a5de1065b3fc/circulationaha.122.059595.fig01.jpg)